Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

Michael O'Riordan

June 26, 2018

News Conference News The Structural Heart Disease Summit 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Presenter: Howard C. Herrmann, Allan Schwartz, Jonathan Afilalo

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

CLINICAL VIEWPOINT: Problems With the Current Practice of Watchful Waiting in Managing Asymptomatic Patients With Severe AS

Presenter: Howard C. Herrmann, Allan Schwartz

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: Howard C. Herrmann, Allan Schwartz, Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: Howard C. Herrmann, Allan Schwartz, Nicolas M. Van Mieghem

June 22, 2018

News Conference News The Structural Heart Disease Summit 2018

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

MitraClip Updates I: Recent Clinical Trial Data and Current OUS Patient Selection Criteria

Presenter: Anthony N. DeMaria, Karl-Heinz Kuck, Anita Asgar

June 21, 2018

Advertisement

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

CLINICAL VIEWPOINT: Problems With the Current Practice of Watchful Waiting in Managing Asymptomatic Patients With Severe AS

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

MitraClip Updates I: Recent Clinical Trial Data and Current OUS Patient Selection Criteria

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content